Please login to the form below

Not currently logged in
Email:
Password:

Transgene

This page shows the latest Transgene news and features for those working in and with pharma, biotech and healthcare.

Novartis and Precision BioSciences announce in vivo gene editing collaboration

Novartis and Precision BioSciences announce in vivo gene editing collaboration

As part of the agreement, Precision will develop a custom ARCUS nuclease designed to insert, in vivo, a therapeutic transgene at a “safe harbour” location in the genome as a potential

Latest news

  • Transgene slumps as viral cancer therapy fails phase 3 trial Transgene slumps as viral cancer therapy fails phase 3 trial

    French biotech Transgene has abandoned a phase 3 trial of its SillaJen-partnered liver cancer therapy after an interim analysis suggested almost no chance of a positive outcome. ... Transgene said in a statement that South Korean biotech SillaJen had

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    However this candidate is based on Transgene’s proprietary next-generation viral platform. ... AstraZeneca has similar plans to combined Transgene’s oncolytic viruses withits in-house pipeline ofImmuno-oncology (IO) treatments.

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Both vectors contain the transgenes for PSA and multiple T-cell co-stimulatory molecules.

  • Sanofi to act as contract manufacturer for Transgene Sanofi to act as contract manufacturer for Transgene

    Sanofi has formed an innovative collaboration with fellow French company Transgene that will see it act at the biotech's contract manufacturing organisation (CMO). ... But in return for its investment Transgene will be its preferred customer for 15 years

  • Regional plans

    As part of the Institut Merieux group, Transgene would be well placed to be able to address the European market with JX 594 for the treatment of solid tumours. ... 181. Transgene/Jennerex ##. JX 594 for the treatment of solid tumours.

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....